Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 02, 2015 6:37 PM ET

Biotechnology

Company Overview of Celldex Therapeutics, Inc.

Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, as well as in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma. It also has various earlier stage drug candidates in clinical de...

Perryville III Building

Suite 200

53 Frontage Road

Hampton, NJ 08827

United States

156 Employees

Phone:

908-200-7500

Fax:

908-454-1911

Key Executives for Celldex Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $814.1K
Executive Vice President, Founder and Chief Scientific Officer
Age: 56
Total Annual Compensation: $543.0K
Chief Financial Officer, Principal Accounting Officer, Senior Vice President, Treasurer and Secretary
Age: 67
Total Annual Compensation: $419.1K
Chief Medical Officer and Executive Vice President
Age: 51
Total Annual Compensation: $556.4K
Chief Business Officer and Senior Vice President
Age: 59
Total Annual Compensation: $419.6K
Compensation as of Fiscal Year 2014.

Celldex Therapeutics, Inc. Key Developments

Celldex Therapeutics, Inc. Promotes Richard Wright to Senior Vice President and Chief Commercial Officer

Celldex Therapeutics, Inc. announced the promotion of Richard Wright, Ph.D. to Senior Vice President and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, including the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex's cancer immunotherapy pipeline.

Celldex Therapeutics, Inc. Announces Independent Data Safety and Monitoring Board Recommends Continuation of Phase 3 Study of RINTEGA(R) (Rindopepimut) in Newly Diagnosed Glioblastoma

Celldex Therapeutics, Inc. announced that an independent Data Safety and Monitoring Board (DSMB) recommended continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed glioblastoma. The ACT IV study is a randomized, double-blind, placebo controlled study of rindopepimut plus GM-CSF added to standard of care temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma. 745 patients were enrolled into ACT IV to reach the required 374 patients with minimal residual disease (assessed by central review) needed for analysis of the primary overall survival endpoint. All patients, including those with disease that exceed this threshold, will be included in a secondary analysis of overall survival as well as analyses of progression-free survival, safety and tolerability, and quality of life. The timing of the overall survival primary endpoint data is event-driven. Interim analyses assessing safety, futility and efficacy conducted by an independent DSMB were prespecified at 50% and 75% of events.

Celldex Therapeutics, Inc. - Special Call

To discuss the ReACT data

Similar Private Companies By Industry

Company Name Region
Adult Stem Cell Corporation of America, Inc. United States
Tyrogenix United States
Carolus Therapeutics, Inc. United States
Epitome Biosystems, Inc. United States
Signum Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celldex Therapeutics, Inc., please visit www.celldextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.